公开(公告)号：WO2021123506A1

公开(公告)日：2021-06-24

申请号：PCT/FI2020/050857

申请日：2020-12-18

申请人： GLYKOS BIOMEDICAL OY

发明人： SATOMAA, Tero ,  SAARINEN, Juhani ,  HELIN, Jari ,  AITIO, Olli ,  PYNNÖNEN, Henna

IPC分类号： A61K47/68 ,  A61P35/00 ,  A61K47/6803 ,  A61K47/6855

摘要： A conjugate is disclosed. The conjugate may be represented by Formula I: [D-O-L]n-T Formula I wherein D is a payload molecule; O is an oxygen atom of said payload molecule; T is a targeting unit capable of binding a target molecule, cell and/or tissue; and n is at least 1.

公开(公告)号：WO2020002765A1

公开(公告)日：2020-01-02

申请号：PCT/FI2019/050480

申请日：2019-06-19

申请人： GLYKOS BIOMEDICAL OY

发明人： SATOMAA, Tero ,  SAARINEN, Juhani

IPC分类号： A61K47/68 ,  A61P35/00

摘要： A conjugate is disclosed. The conjugate may comprise a targeting unit for delivery to a target tissue, and a Galectin inhibitor for inhibiting Galectin interaction within the target tissue, wherein the Galectin inhibitor is conjugated to the targeting unit.

公开(公告)号：WO2019243672A1

公开(公告)日：2019-12-26

申请号：PCT/FI2019/050479

申请日：2019-06-19

申请人： GLYKOS BIOMEDICAL OY

发明人： SAARINEN, Juhani ,  SATOMAA, Tero ,  AITIO, Olli

IPC分类号： A61K47/68 ,  A61P35/00

摘要： A conjugate is disclosed. The conjugate may comprise a targeting unit for delivery to a tumour, and a glycosylation inhibitor for inhibiting glycosylation in the tumour, thereby decreasing the immunosuppressive activity of the tumour. The glycosylation inhibitor may be conjugated to the targeting unit.